Kinesin Family Member C3: A Potential Drug Target and Biomarker

Target Name: KIFC3

NCBI ID: G3801

KIFC3

Kinesin Family Member C3: A Potential Drug Target and Biomarker

The Kinesin family is an important protein family responsible for protein transport within cells, and its C3 member plays a key role in cells. C3 protein consists of two subunits, each subunit contains a hydrophobic C3 domain and a hydrophilic N-terminus. The C3 subunit has multiple functions, including binding to substrates, regulating the cell cycle, and participating in apoptosis. During the occurrence and development of tumors, the variation and abnormal expression of the C3 subunit has been considered to be an important factor.

In recent years, researchers have conducted in-depth studies on the role of the C3 subunit in tumorigenesis. Many studies have shown that variation and abnormal expression of C3 subunits are closely related to tumor progression and invasion ability. In addition, the expression level of C3 subunit is also significantly related to the survival rate of tumor patients. These findings suggest that the C3 subunit has important potential in tumor treatment and is valuable as a drug target.

As a drug target, research on the C3 subunit has received widespread attention. Many researchers have attempted to develop drugs that interfere with the function of the C3 subunit to inhibit tumor growth and progression. Currently, some studies are exploring the use of small molecule drugs and antibody conjugation technologies to specifically interfere with the function of the C3 subunit. These drugs include inhibitors of C3 activity, C3-specific antibodies, and chimeric antibodies. These drugs can inhibit the growth and progression of tumor cells by interfering with the binding of C3 subunits to substrates, regulating the cell cycle, and affecting cell apoptosis.

As a biomarker, the C3 subunit also has great potential. Since the expression level of C3 subunit in tumors is closely related to tumor progression and invasion ability, the survival rate of tumor patients can be predicted by detecting the expression level of C3 subunit. In addition, the expression level of C3 subunit can also be used as an indicator of tumor progression, helping doctors to detect tumor progression and recurrence in a timely manner.

The abnormal expression of C3 subunit has always been one of the hot spots in tumor research. Many studies have shown that abnormal expression of C3 subunit is closely related to tumor progression and invasion ability. For example, some studies have found that the expression levels of C3A and C3B are significantly related to the invasive ability of tumors. In addition, some studies have also found that the abnormal expression of C3 subunit is closely related to the apoptosis resistance of tumors. These findings suggest that abnormal expression of the C3 subunit may be an important predictor of tumor progression and recurrence.

The role of C3 subunit in tumor treatment does not stop there. Some studies also show that the C3 subunit can regulate the cell cycle and participate in processes such as apoptosis. These findings suggest that the C3 subunit may have multiple mechanisms of action in tumor treatment, providing new ideas and methods for tumor treatment.

In summary, C3 family member C3 has important potential in tumor occurrence and development and is valuable as a drug target. By inhibiting the function of the C3 subunit, the growth and progression of tumor cells can be inhibited, providing new methods and ideas for tumor treatment. At the same time, the expression level of C3 subunit can also be used as a predictor of tumor progression and recurrence, providing important reference value for tumor treatment. Therefore, future research on C3 family member C3 will continue to receive widespread attention and bring more hope for tumor treatment.

Protein Name: Kinesin Family Member C3

Functions: Minus-end microtubule-dependent motor protein. Involved in apically targeted transport (By similarity). Required for zonula adherens maintenance

The "KIFC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIFC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets